Search clinical trials for: Anlotinib Hydrochloride

Total 7920 results

M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Skin Cancer

United States
Hoffmann-La Roche

Terminated

A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Head and Neck Cancer

Spain
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
Wenzhou Medical University

Unknown

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Esophageal Cancer

China
University of California, Davis
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

Pancreatic Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Daiichi Sankyo Co., Ltd.
ICON Clinical Research

Completed

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Konstantin Dragnev
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Carcinoma, Non-small-cell Lung

United States
Astellas Pharma Inc

Completed

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

United Kingdom, United States, Brazil, Canada, Germany, Korea, Republic of, Poland, Romania, Russian Federation
Grupo Gallego de Investigaciones Oncologicas

Completed

Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients (XELTA)

Metastatic Adenocarcinoma of the Pancreas

Spain
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Zhongda Hospital

Recruiting

TACE Combined With Penpulimab and Anlotinib for Advanced HCC

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Zhengzhou University
First Affiliated Hospital of Xinjiang Medical University; Anyang Tumor Hospital and other collaborators

Recruiting

Treatment of Advanced Intrahepatic Cholangiocarcinoma (TAICC)

ICC

China
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Rectal Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Stage III Non-small-cell Lung Cancer

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Lung Cancer | Lung Cancer Metastatic | Lung Adenocarcinoma | Lung Cancer Stage IV | Recurrent Lung Adenocarcinoma | Recurrent Lung Cancer

United States
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Shanghai Gopherwood Biotech Co., Ltd.

Not yet recruiting

BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer (CAN-RESPOND)

Endometrial Cancer
Henan Cancer Hospital

Recruiting

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Desmoid

China
Shanghai Chest Hospital
3D Medicines

Not yet recruiting

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Non-Small Cell Lung Cancer
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Anhui Shi, MD
Peking University Cancer Hospital & Institute; Chia Tai Tianqing Pharmaceutical...

Completed

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (ALTER-L029)

Non-Small Cell Lung Cancer Stage III

China
Taizhou Hospital

Completed

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Small Cell Lung Cancer Recurrent

China
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital; Yan'an University Affiliated Hospital

Unknown

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Non-squamous NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Esophageal Squamous Cell Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Gastric Cancer

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Zhejiang University

Recruiting

TAS-102 and Anlotinib in ≥3 Lines mGC

Gastric Cancer

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Hunan Cancer Hospital

Completed

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Metastatic Breast Cancer

China
Shanghai Minimally Invasive Surgery Center

Withdrawn

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Rectal Cancer | Anlotinib | Neoadjuvant Treatment
Shanghai Changzheng Hospital

Unknown

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Gastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Io Therapeutics
Dartmouth College

Suspended

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Lung Cancer, Nonsmall Cell

United States
Hoffmann-La Roche

Completed

A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

France
M.D. Anderson Cancer Center
Genentech, Inc.; Vanderbilt-Ingram Cancer Center

Completed

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Lung Cancer

United States
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
Xijing Hospital

Not yet recruiting

Adjuvant Treatment of Digestive Tract Tumors (ATDTT)

Adjuvant Treatment
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Lung Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Sun Yat-sen University

Recruiting

Newly Diagnosed Glioblastoma

Glioblastoma

China
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Syndax Pharmaceuticals

Terminated

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Non Small Cell Lung Cancer

United States

Search clinical trials for: Anlotinib Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations